Paul A. Mahon - Mar 3, 2022 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
EVP & GENERAL COUNSEL
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Stock symbol
UTHR
Transactions as of
Mar 3, 2022
Transactions value $
-$378,715
Form type
4
Date filed
3/4/2022, 03:35 PM
Previous filing
Feb 18, 2022
Next filing
Mar 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $666K +6K +16.5% $111.00 42.4K Mar 3, 2022 Direct F1
transaction UTHR Common Stock Sale -$975K -5.6K -13.22% $174.08 36.8K Mar 3, 2022 Direct F1, F2
transaction UTHR Common Stock Sale -$69.9K -400 -1.09% $174.70 36.4K Mar 3, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Options Options Exercise $0 -6K -9.29% $0.00 58.6K Mar 3, 2022 Common Stock 6K $111.00 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $173.58 to $174.455. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $174.59 to $174.895. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021